Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson’s Disease
- Monday, October 4, 2021, 7:13
- Environment
- Add a comment
ATLANTA, Oct. 4, 2021 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced interim three-month results…
About the Author
adminasapcorp has written 41532 stories on this site.